$95.3 M

APRE Mkt cap, 22-Sept-2021
Aprea Therapeutics Net income (Q1, 2021)-9.7 M
Aprea Therapeutics Cash, 31-Mar-202177.6 M
Aprea Therapeutics EV18 M
Get notified regarding key financial metrics and revenue changes at Aprea TherapeuticsLearn more
Banner background

Aprea Therapeutics Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

R&D expense

13.4m14.2m21.0m37.9m

General and administrative expense

2.5m2.3m8.6m14.9m

Operating expense total

15.9m16.5m29.5m52.8m

Interest expense

15.0182.0156.4k222.7k

Income tax expense

Net Income

(15.2m)(15.5m)(28.1m)(53.5m)

Quarterly

USDQ3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

R&D expense

4.9m9.1m10.7m8.8m6.8m

General and administrative expense

2.3m2.8m3.8m3.5m3.4m

Operating expense total

7.2m11.9m14.5m12.2m10.2m

Interest expense

6.1k224.4k2.7k9.2k1.1k

Net Income

(6.2m)(9.4m)(16.4m)(12.3m)(9.7m)

Aprea Therapeutics Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020

Cash

65.7m130.1m89.0m

Prepaid Expenses

3.0m3.4m

Current Assets

66.0m133.0m92.4m

PP&E

24.5k41.6k38.5k

Total Assets

133.6m92.8m

Accounts Payable

1.7m2.2m4.5m

Short-term debt

242.3k256.3k

Current Liabilities

4.9m9.1m15.3m

Long-term debt

302.6k78.8k

Total Debt

545.0k335.2k

Total Liabilities

4.9m9.4m15.4m

Common Stock

127.1k21.0k21.2k

Preferred Stock

112.6m

Additional Paid-in Capital

19.7m226.3m231.4m

Retained Earnings

(62.5m)(90.5m)(144.0m)

Total Equity

(51.4m)124.2m77.4m

Financial Leverage

1.1 x1.2 x

Aprea Therapeutics Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(15.2m)(15.5m)(28.1m)(53.5m)

Depreciation and Amortization

7.9k8.3k11.1k28.8k

Accounts Payable

327.1k214.4k437.5k2.3m

Cash From Operating Activities

(14.0m)(15.3m)(26.7m)(41.8m)

Purchases of PP&E

(3.7k)(30.9k)(25.7k)

Cash From Investing Activities

(3.7k)(30.9k)(25.7k)

Cash From Financing Activities

23.3m56.4m92.6m150.9k

Net Change in Cash

9.3m41.1m65.8m(41.7m)

Quarterly

USDQ2, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(7.7m)(8.7m)(15.0m)(9.4m)(25.8m)(38.1m)(9.7m)

Depreciation and Amortization

4.3k4.7k8.9k3.8k7.9k12.2k3.6k

Accounts Payable

(51.4k)640.7k2.0m829.8k3.3m2.2m(1.0m)

Cash From Operating Activities

(8.2m)(9.8m)(16.2m)(7.5m)(17.2m)(28.6m)(11.5m)

Purchases of PP&E

(4.7k)(6.2k)(16.4k)(12.2k)(10.1k)(9.4k)

Cash From Investing Activities

(4.7k)(6.2k)(16.4k)(12.2k)(10.1k)(9.4k)

Cash From Financing Activities

1.4k5.6m5.6m29.5k150.9k150.9k

Net Change in Cash

(8.3m)(4.2m)(10.6m)(7.5m)(17.0m)(28.5m)(11.5m)

Aprea Therapeutics Ratios

USDFY, 2017

Aprea Therapeutics Operating Metrics

Sep, 2019

Phase II Trials Products (Frontline)

2

Phase II Trials Products (Post-Transplant Maintenance)

1

Phase III Trials Products (Frontline)

1

Pre-Clinical Phase Products

1

Preclinical Phase Products (Frontline and Relapsed / Refractory)

1